ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

FORMULATION AND EVALUATION OF MATRIX TYPE TRANSDERMAL PATCHES OF ATENOLOL AND STUDY THE EFFECT OF PERMEATION ENHANCER

AUTHORS:

Mr. VIJAY BAHADUR MAURYA,Dr. VINAY KUMAR, Mr. RAJEEV KUMAR,

ABSTRACT:

Transdermal drug delivery attaining much focus in the field of topical administration of dosage form for systematic circulation. The structure and composition of skin is major obstacle of this route which makes it impermeable for most of the substances. Its impermeability may be altered with the specific techniques like physical approaches or prodrug or uses of chemical enhancer. Atenolol is a selective β1 receptor blocker and effective in treatment of hypertension. The oral administration of its having short biological half life approximately 6 hours and due to extensive first pass metabolism only 45% reaches in the systemic circulation. Therefore need of a suitable type of dosage form of drug which is able to avoid the above subsidence for the systemic circulation. The results showed Atenolol-HPMC-PVP patches having good physicochemical properties like appearance, weight variation, drug content, thickness, folding endurance. Moisture absorption and WVTR studied showed that patches were able to maintain their integrity. The cumulative in-vitro drug release was performed in phosphate buffer pH 7.4, in present study formulation HP1 exhibit 14.21±2.1 to 72.77±2.2, HP2 exhibit 17.35±1.8 to 76.32±2.8, HP3 exhibit 18.41±1.1 and HP4 exhibit 18.32±1.5 to 83.76±2.1 percent of release. In- vitro permeation studies were done on wistar rat skin. DMSO 1%w/w was used as permeation enhancer which significantly increased the cumulative permeated amount of atenlol. The permeation followed as HP1 exhibit 5.12±0.6 to 43.67±2.5, HP2 exhibit 6.03±0.3 to 51.83.HP3 exhibit 6.97±1.3 to 55.02±1.1, HP4 exhibit 8.48±1.5 to 57.53±1.5, HP5 exhibit 8.13±0.8 to 47.88±2.8, HP6 exhibit 10.15±0.9 to 55.58±2.3, HP7 exhibit 11.56±1.2 to 60.97±1.6 and HP8 exhibit 12.8±1.5 to 65.83±2.0 percent of release. The method devised to prepare the patches was effective and reproducible. The patches formed were uniform with respect to physicochemical characteristics. In-vitro and In-vivo permeation of atenolol was better because of its hydrophilic nature exert an interaction with water soluble polymers resulted an increased drug release. The results showed that matrix type atenolol transdermal patches could be developed and administered via topical route over a prolonged period. Keywords:TDDS, Permeation enhancer, Systemic circulation, First pass metabolism, Atenolol,

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.